W

Wits Clinical Research | WCR Chris Hani Baragwanath Clinical Trial Site

Research site
(Unclaimed)
Location
26 Chris Hani Road, Johannesburg, Guateng, South Africa
Site insights

Top conditions

Gastroparesis (4 trials)

Crohn Disease (3 trials)

Breast Cancer (3 trials)

Carcinoma (2 trials)

Inflammation (2 trials)

Top treatments

Relamorelin
Semaglutide
INCB099280
PF-00547659
Sacituzumab
Ziltivekimab
PF-00489791
Enzalutamide
Sunitinib
Pemafibrate

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

14 of 30
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

The purpose of this study is to learn about the effects of three study medicines (encorafenib, binimetinib, and pembrolizumab) given together for the...

Active, not recruiting
Melanoma
Drug: Binimetinib
Drug: Encorafenib

This study will be done to see if ziltivekimab can be used to treat people living with heart failure and inflammation. Participants will either get z...

Enrolling
Heart Failure
Drug: Placebo
Drug: Ziltivekimab

This is a Phase 2/3 study that comprises 5 substudies designed to evaluate the efficacy, safety, and tolerability of oral etrasimod as therapy in adu...

Enrolling
Crohn's Disease
Drug: Etrasimod
Drug: Placebo
Locations recently updated

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced Cutaneous S...

Enrolling
Cutaneous Squamous Cell Carcinoma
Drug: INCB099280

This study is being conducted to determine the safety, tolerability, and preliminary efficacy of INCB099280 in participants with advanced solid tumor...

Enrolling
Advanced Solid Tumor
Drug: INCB099280

A study to learn about a new medicine called ARV-471 (PF-07850327) in people who have advanced metastatic breast cancer.

Enrolling
Advanced Breast Cancer
Drug: Fulvestrant
Drug: ARV-471

The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07220060 and PF-07104091) in people with...

Enrolling
Breast Cancer
Solid Tumors
Drug: PF-07220060 + PF-07104091 combination dose escalation
Drug: PF-07104091 + PF-07220060 + fulvestrant dose expansion
Locations recently updated

The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants...

Enrolling
Melanoma
Renal Cell Carcinoma (RCC)
Drug: INCB 99280 with Ipilimumab

A randomized, multi-center, double-blind, three arm placebo-controlled study in male and non-pregnant, non-lactating female subjects aged 18 years to...

Enrolling
Ulcerative Proctitis
Combination Product: Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator
Combination Product: Twice daily placebo suppository administered with Sephure applicator

The purpose of this study is to assess the efficacy and safety of platinum-based chemotherapy with or without INCMGA00012 in participants with metast...

Active, not recruiting
Metastatic Nonsquamous Non-Small Cell Lung Cancer
Metastatic Squamous Non-Small Cell Lung Cancer
Drug: nab-Paclitaxel
Drug: Paclitaxel

Semaglutide is a medicine studied in patients with NASH. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabe...

Enrolling
Non-alcoholic Steatohepatitis
Drug: Placebo
Drug: Semaglutide

The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of phy...

Enrolling
Triple Negative Breast Cancer
PD-L1 Negative
Drug: Paclitaxel
Drug: Gemcitabine

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of tal...

Active, not recruiting
mCRPC
Drug: Talazoparib with enzalutamide
Drug: Placebo with enzalutamide

This study is conducted to see if ziltivekimab reduces the risk of having cardiovascular events (for example heart attack and stroke) in people with...

Enrolling
Chronic Kidney Disease
Inflammation
Drug: Ziltivekimab C
Drug: Placebo (Ziltivekimab B)

Trial sponsors

Pfizer logo

Pfizer (8 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems